Literature DB >> 17356079

Lung CT densitometry in systemic sclerosis: correlation with lung function, exercise testing, and quality of life.

Gianna Camiciottoli1, Ilaria Orlandi2, Maurizio Bartolucci2, Eleonora Meoni3, Francesca Nacci3, Stefano Diciotti4, Chiara Barcaroli2, Maria Letizia Conforti5, Massimo Pistolesi3, Marco Matucci-Cerinic5, Mario Mascalchi2.   

Abstract

BACKGROUND: To ascertain if analysis of lung density histograms in thin-section CT was more reproducible than visual assessment of lung changes in systemic sclerosis (SSc), and if such density histogram parameters as mean lung attenuation (MLA), skewness, and kurtosis could more closely reflect pulmonary function as well as exercise and quality of life impairment.
METHODS: The intraoperator and interoperator reproducibility of visual and densitometric lung CT analysis in 48 SSc patients examined with CT were evaluated by means of weighted kappa statistics. Univariate and multivariate regression analyses were applied to evaluate the relationship of visual and densitometric CT measurements with functional parameters including functional residual capacity (FRC), FVC, FEV(1), diffusion capacity of the lung for carbon monoxide (Dlco), 6-min walking testing (6MWT), and health-related quality of life questionnaire (QLQ) parameters.
RESULTS: The intraoperator and interoperator reproducibility of MLA (intraobserver weighted kappa = 0.97; interobserver weighted kappa = 0.96), skewness (intraobserver weighted kappa = 0.89; interobserver weighted kappa = 0.88), and kurtosis (intraobserver weighted kappa = 0.89; interobserver weighted kappa = 0.88) were higher than those of visual assessment (intraobserver weighted kappa = 0.71; interobserver weighted kappa = 0.69). In univariate analysis, only densitometric measurements were correlated with some exercise and QLQ parameters. In multivariate analysis, MLA (square regression coefficient corrected [R(2)c] = 0.70), skewness (R(2)c = 0.78), and kurtosis (R(2)c = 0.77) were predicted by FRC, FVC, Dlco, 6MWT, and QLQ parameters, while visual assessment was associated only with FRC and FVC (R(2)c = 0.40).
CONCLUSIONS: In SSc, densitometric analysis is more reproducible than visual assessment of lung changes in thin-section CT and more closely correlated to pulmonary function testing, 6MWT, and QLQ. Density histogram parameters may be useful for cross-sectional and longitudinal studies of lung involvement in SSc.

Entities:  

Mesh:

Year:  2007        PMID: 17356079     DOI: 10.1378/chest.06-1401

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  28 in total

1.  Utility of an open-source DICOM viewer software (OsiriX) to assess pulmonary fibrosis in systemic sclerosis: preliminary results.

Authors:  Alarico Ariani; Marina Carotti; Marwin Gutierrez; Elisabetta Bichisecchi; Walter Grassi; Gian Marco Giuseppetti; Fausto Salaffi
Journal:  Rheumatol Int       Date:  2013-08-15       Impact factor: 2.631

2.  The impact of slice-reduced computed tomography on histogram-based densitometry assessment of lung fibrosis in patients with systemic sclerosis.

Authors:  Thi Dan Linh Nguyen-Kim; Britta Maurer; Yossra A Suliman; Fabian Morsbach; Oliver Distler; Thomas Frauenfelder
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

3.  Quantitative computed tomography detects interstitial lung diseases proven by biopsy.

Authors:  Alarico Ariani; Andrea Imperatori; Massimo Castiglioni; Elisa Daffrè; Marina Aiello; Giuseppina Bertorelli; Alfredo Chetta; Lorenzo Dominioni; Nicola Rotolo
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

4.  Quantitative diagnosis of connective tissue disease-associated interstitial pneumonia using thoracic computed tomography images.

Authors:  Nobuko Tosaka Ozuno; Hokuto Akamatsu; Hiroshi Takahashi; Naoko Fujii; Shunji Yoshida
Journal:  Clin Rheumatol       Date:  2015-10-31       Impact factor: 2.980

5.  Automated 3D ιnterstitial lung disease εxtent quantification: performance evaluation and correlation to PFTs.

Authors:  Alexandra Kazantzi; Lena Costaridou; Spyros Skiadopoulos; Panayiotis Korfiatis; Anna Karahaliou; Dimitris Daoussis; Andreas Andonopoulos; Christina Kalogeropoulou
Journal:  J Digit Imaging       Date:  2014-06       Impact factor: 4.056

6.  A computer-aided diagnosis system for quantitative scoring of extent of lung fibrosis in scleroderma patients.

Authors:  H G Kim; D P Tashkin; P J Clements; G Li; M S Brown; R Elashoff; D W Gjertson; F Abtin; D A Lynch; D C Strollo; J G Goldin
Journal:  Clin Exp Rheumatol       Date:  2010-11-03       Impact factor: 4.473

Review 7.  Pulmonary quantitative CT imaging in focal and diffuse disease: current research and clinical applications.

Authors:  Mario Silva; Gianluca Milanese; Valeria Seletti; Alarico Ariani; Nicola Sverzellati
Journal:  Br J Radiol       Date:  2018-01-12       Impact factor: 3.039

8.  Assessment of lung involvement in sarcoidosis - the use of an open-source software to quantify data from computed tomography.

Authors:  Tomaz Urbankowski; Lucyna Opoka; Paweł Wojtan; Rafal Krenke
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

9.  Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide.

Authors:  Hyun J Kim; Matthew S Brown; Robert Elashoff; Gang Li; David W Gjertson; David A Lynch; Diane C Strollo; Eric Kleerup; Daniel Chong; Sumit K Shah; Shama Ahmad; Fereidoun Abtin; Donald P Tashkin; Jonathan G Goldin
Journal:  Eur Radiol       Date:  2011-09-17       Impact factor: 5.315

10.  Shrinking lung syndrome as a manifestation of pleuritis: a new model based on pulmonary physiological studies.

Authors:  Lauren A Henderson; Stephen H Loring; Ritu R Gill; Katherine P Liao; Rumey Ishizawar; Susan Kim; Robin Perlmutter-Goldenson; Deborah Rothman; Mary Beth F Son; Matthew L Stoll; Lawrence S Zemel; Christy Sandborg; Paul F Dellaripa; Peter A Nigrovic
Journal:  J Rheumatol       Date:  2013-02-01       Impact factor: 4.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.